Fifty-three patients with PTSD and alcoholism were admitted for 4 weeks to an inpatient unit at the NIH Clinical Center and randomized to double-blind aprepitant ( 125 mg/day ; based on PET studies reporting > 90 % central receptor occupancy at this dose ) or placebo .